|
rs113488022
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Epithelioid GBM with BRAF V600E mutation can be considered a good treatment indication for precision medicine, and this patient-derived cell line should be useful for prediction of the tumor response and clarification of its biological characteristics.
|
31345255 |
2019 |
|
rs113488022
|
|
|
0.090 |
GeneticVariation |
BEFREE |
BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma.
|
30013630 |
2018 |
|
rs113488022
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Here, we describe a case of systemic metastases of a clonal subpopulation of BRAF V600E mutated glioblastoma in a patient previously treated with surgery, radiation, temozolomide and bevacizumab.
|
29744614 |
2018 |
|
rs113488022
|
|
|
0.090 |
GeneticVariation |
BEFREE |
These findings suggest that epithelioid GBM may arise from a PXA with a BRAF V600E mutation.
|
24894018 |
2014 |
|
rs113488022
|
|
|
0.090 |
GeneticVariation |
BEFREE |
BRAF V600E mutational analyses should be performed on E-GBMs, particularly in all pediatric and young-aged adults, given the potential for BRAF inhibitor therapy in this subset of GBM patients.
|
23552385 |
2013 |
|
rs113488022
|
|
|
0.090 |
GeneticVariation |
BEFREE |
An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 subependymal giant cell astrocytomas (SEGAs), 12 glioblastoma with neuronal marker expression (GBM-N), and 28 pleomorphic xanthoastrocytomas (PXAs)) from 100 patients were investigated for the presence of BRAF(V600E) by direct sequencing.
|
25346165 |
2015 |
|
rs113488022
|
|
|
0.090 |
GeneticVariation |
BEFREE |
This case suggests that the BRAF V600E mutation may be involved in the malignant transformation to glioblastoma.
|
26404554 |
2016 |
|
rs113488022
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Epithelioid glioblastoma is a recognized glioblastoma variant, recently added to the World Health Organization brain tumor classification, with similar prognosis as the classic variant and B-Raf V600E mutations in 50% of the cases.
|
31258848 |
2019 |
|
rs1135401891
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Here, we report on the expression of wild-type and L441P variants of human PO in a U87 glioblastoma human cell line in an attempt to assess their effect on glutamate metabolism.
|
29694413 |
2018 |
|
rs1136410
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The C allele of the PARP1 rs1136410 variant was associated with a 20% reduction in risk for glioblastoma multiforme (odds ratio(CT or CC), 0.80; 95% confidence interval, 0.67-0.95).
|
19318434 |
2009 |
|
rs1138272
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, the significant risk elevation is present between GSTP1 A114V genotype and other histopathologic glioma except GBM.
|
23079710 |
2013 |
|
rs11515
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The analysis of CDKN2A showed NDTMM GBMs had an increased minor allele frequency for the C500G (rs11515) polymorphism compared to those with telomerase and ALT positive GBMs (p = 0.002).
|
22046342 |
2011 |
|
rs11548193
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Taken together, the MS and novel 3D structural data give us reason to further pursue BCAT2 T186R as a precision drug target in GBM.Graphical Abstract ᅟ.
|
28681360 |
2017 |
|
rs11554137
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Clinical prognostic value of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in glioblastoma.
|
29423539 |
2018 |
|
rs11558961
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, rs11558961 might influence the chemoresistance and progression of GBM cells via promoting the binding of miR-139, ultimately decrease the susceptibility of GBM.
|
29746255 |
2018 |
|
rs11571833
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Although no single variant showed an association which was statistically significant at the genome-wide threshold a number represented promising associations - BRCA2:c.9976A>T, p.(Lys3326Ter), which has been shown to influence breast and lung cancer risk (odds ratio (OR)=2.3, P=4.00 × 10(-4) for glioblastoma (GBM)) and IDH2:c.782G>A, p.(Arg261His) (OR=3.21, P=7.67 × 10(-3), for non-GBM).
|
26264438 |
2016 |
|
rs1161136341
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The R132H mutation in isocitrate dehydrogenase 1 (IDH1<sup>R132H</sup>) is commonly observed and associated with better survival in glioblastoma multiforme (GBM), a malignant brain tumor.
|
31151327 |
2019 |
|
rs11615
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, the haplotype containing the C allele of ERCC2 rs13181 polymorphism and the T allele of ERCC1 rs11615 polymorphism was significantly associated with a protective effect of developing glioblastoma (OR=0.34, 95% CI 0.16-0.71; P=0.004).
|
24325908 |
2014 |
|
rs11670188
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified LIG4 rs7325927 and BTBD2 rs11670188 as predictors of STS in GBM and CCDC26 rs10464870 and rs891835, HMGA2 rs1563834, and RTEL1 rs2297440 as predictors of LTS.
|
20368557 |
2010 |
|
rs118101777
|
|
|
0.080 |
GeneticVariation |
BEFREE |
HMab-2 detected endogenous IDH1-R132H protein expressed in glioblastoma in immunohistochemical analysis.
|
26381180 |
2015 |
|
rs118101777
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Although no single variant showed an association which was statistically significant at the genome-wide threshold a number represented promising associations - BRCA2:c.9976A>T, p.(Lys3326Ter), which has been shown to influence breast and lung cancer risk (odds ratio (OR)=2.3, P=4.00 × 10(-4) for glioblastoma (GBM)) and IDH2:c.782G>A, p.(Arg261His) (OR=3.21, P=7.67 × 10(-3), for non-GBM).
|
26264438 |
2016 |
|
rs118101777
|
|
|
0.080 |
GeneticVariation |
BEFREE |
We identified a small cohort of WHO grade II-III astrocytomas that harbored the IDH1 R132H mutation, as confirmed by both immunohistochemistry and molecular sequence analysis, which nonetheless had unexpectedly rapid recurrence and subsequent progression to glioblastoma.
|
28421459 |
2017 |
|
rs118101777
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The prognostic value of IDH1 R132H mutation in GBM patients was verified.
|
24511544 |
2014 |
|
rs118101777
|
|
|
0.080 |
GeneticVariation |
BEFREE |
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
|
25427834 |
2015 |
|
rs118101777
|
|
|
0.080 |
GeneticVariation |
BEFREE |
For this reason, it was suggested that immunohistochemistry against IDH1 R132H is sufficient to classify GBM as IDH wild-type in this age group.
|
31758617 |
2020 |